Pulmonary Arterial Remodeling Induced by a Th2 Immune Response
Overview
General Medicine
Authors
Affiliations
Pulmonary arterial remodeling characterized by increased vascular smooth muscle density is a common lesion seen in pulmonary arterial hypertension (PAH), a deadly condition. Clinical correlation studies have suggested an immune pathogenesis of pulmonary arterial remodeling, but experimental proof has been lacking. We show that immunization and prolonged intermittent challenge via the airways with either of two different soluble antigens induced severe muscularization in small- to medium-sized pulmonary arteries. Depletion of CD4(+) T cells, antigen-specific T helper type 2 (Th2) response, or the pathogenic Th2 cytokine interleukin 13 significantly ameliorated pulmonary arterial muscularization. The severity of pulmonary arterial muscularization was associated with increased numbers of epithelial cells and macrophages that expressed a smooth muscle cell mitogen, resistin-like molecule alpha, but surprisingly, there was no correlation with pulmonary hypertension. Our data are the first to provide experimental proof that the adaptive immune response to a soluble antigen is sufficient to cause severe pulmonary arterial muscularization, and support the clinical observations in pediatric patients and in companion animals that muscularization represents one of several injurious events to the pulmonary artery that may collectively contribute to PAH.
Intestinal IFNα4 promotes 15-HETE diet-induced pulmonary hypertension.
Ruffenach G, Medzikovic L, Aryan L, Sun W, Lertpanit L, OConnor E Respir Res. 2024; 25(1):419.
PMID: 39609844 PMC: 11606228. DOI: 10.1186/s12931-024-03046-z.
Circulating free heme induces cytokine storm and pulmonary hypertension through the MKK3/p38 axis.
Valuparampil Varghese M, James J, Bharti D, Rischard F, Rafikova O, Rafikov R Am J Physiol Lung Cell Mol Physiol. 2024; 327(4):L574-L586.
PMID: 39197168 PMC: 11482467. DOI: 10.1152/ajplung.00422.2022.
Inhibition of immunoglobulin E attenuates pulmonary hypertension.
Shu T, Liu Y, Zhou Y, Zhou Z, Li B, Xing Y Nat Cardiovasc Res. 2024; 1(7):665-678.
PMID: 39196237 DOI: 10.1038/s44161-022-00095-9.
Bibliometric analysis of T-cells immunity in pulmonary hypertension from 1992 to 2022.
Chen X, Yan Z, Pan Q, Zhang C, Chen Y, Liang X Immun Inflamm Dis. 2024; 12(7):e1280.
PMID: 38967362 PMC: 11225084. DOI: 10.1002/iid3.1280.
Resistin predicts disease severity and survival in patients with pulmonary arterial hypertension.
Gao L, Skinner J, Nath T, Lin Q, Griffiths M, Damico R Respir Res. 2024; 25(1):235.
PMID: 38844967 PMC: 11154998. DOI: 10.1186/s12931-024-02861-8.